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ABSTRACT
PURPOSE: Leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) 
is a cancer stem cell marker and a down-stream target in Wnt/β-catenin signaling. 
In human papillary thyroid cancer (PTC), over activation of Wnt/β-catenin has been 
associated with tumor aggressiveness.
PATIENTS AND METHODS: Using established human cell lines (TPC-1, KTC-1, 
Nthy-ori-3–1), we report LGR5 and R-spondin (RSPO1–3) overexpression in PTC and 
manipulate LGR5 and Wnt/β-catenin signaling via both pharmacologic and genetic 
interventions. We test the association of LGR5 tumor expression with markers of 
PTC aggressiveness using a Discovery Cohort (n = 26 patients) and a Validation 
Cohort (n = 157 patients). Lastly, we explore the association between LGR5 and the 
BRAFV600E mutation (n = 33 patients).
RESULTS: Our results reveal that LGR5 and its ligand, RSPO, are overexpressed 
in human PTC, whereby Wnt/β-catenin signaling regulates LGR5 expression and 
promotes cellular migration. In two separate cohorts of patients, LGR5 and RSPO2 
were associated with markers of tumor aggressiveness including: lymph node 
metastases, vascular invasion, increased tumor size, aggressive histology, advanced 
AJCC TNM stage, microscopic extra thyroidal extension, capsular invasion, and 
macroscopic invasion. As a biomarker, LGR5 positivity predicts lymph node metastasis 
with 95.5% sensitivity (95% CI 88.8%-98.7%) and 61% specificity (95% CI: 48.4%–
72.4%) and has a negative predictive value (NPV) of 91.3% (95% CI 79.2%–97.5%) 
for lymph node metastatic disease. In human PTC, LGR5 is also strongly associated 
with the BRAFV600E mutation (p = 0.005).
CONCLUSION: We conclude that overexpression of LGR5 is associated with 
markers of tumor aggressiveness in human PTC. LGR5 may serve as a future potential 
biomarker for patient risk stratification and loco regional metastases in PTC.
INTRODUCTION
The Wnt/β-catenin signaling pathway plays 
an important role in stem cell proliferation, tissue 
differentiation, and cellular polarity [1–2]. Dysregulation 
of Wnt/β-catenin signaling contributes to the development 
of human papillary thyroid cancer (PTC), potentiating 
cancer stem cell proliferation, disruption of thyroid 
microarchitecture, tumor dedifferentiation, extra capsular 
spread, and angioinvasion [3–5]. Recently, theories 
on thyroid cancer biogenesis have migrated from the 
classical explanation (i.e “multi-hit” genetic mutations 
and environmental exposures) to the promotion of tumor- 
genesis by proliferation of cancer stem cells (CSCs) [6–7]. 
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In the CSC hypothesis, embryonic cells in the thyroid gland 
(i.e. thyroblasts and prothyrocytes) are susceptible to tumor 
formation and accumulate mutations that give rise to thyroid 
cancer.
Leucine-rich repeat-containing G-protein-coupled 
receptor 5 (LGR5) is specifically expressed on CSCs and 
is a known downstream target gene of the Wnt/β-catenin 
pathway [8–12]. The LGR5 receptor is structurally 
similar to the thyroid-stimulating hormone (TSH) 
receptor [13], consistent with a role for LGR5 in thyroid 
pathophysiology. Recently, LGR5 has been shown to 
bind with high affinity to a family of secreted growth 
factor ligands known as R-spondins (RSPO1–4) [14]. 
The four paralogs share 40–60% pairwise amino acid 
sequence identity and are predicted to share substantial 
structural homologies. A characteristic feature of all four 
RSPO members is their ability to activate LGR5-frizzled 
lipoprotein receptor-related protein 5 and 6 (LRP5/6) 
binding and enhance Wnt-mediated β-catenin activation. 
[15–20].
In recent years, multiple studies have demonstrated 
that LGR5 is overexpressed in various types of tumors, 
including colorectal [21], ovarian [22], hepatocellular 
[23], basal cell [24], and esophageal cancers [25]. In 
several of these cancers, high LGR5 expression is 
associated with the initiation, invasion, and metastasis 
of tumors, suggesting a potential role for LGR5 in 
tumor genesis [26, 27]. Still, controversial literature 
exists claiming that LGR5 is a negative regulator of 
tumorigenicity [28, 29]. We tested the hypothesis 
that overexpression of the CSC marker, LGR5, is 
associated with markers of thyroid tumor aggressiveness, 
including cellular migration, features of histological 
aggressiveness, loco-regional metastases, and presence 
of the BRAFV600E mutation.
RESULTS
LGR5 and RSPO are overexpressed in human 
papillary thyroid cancer
Using established in vitro models and human samples, 
we found that the LGR5 receptor and its R-spondin 
ligands (RSPO 1–3) are overexpressed in human PTC 
[Figures 1A–1D]. Consistent with published literature 
stating that RSPOs are functional ligands for the LGR5 
receptor, we confirm dose-dependent up-regulation of 
LGR5 in the presence of RSPO ligand [Figures 2A, 2C]. 
In addition to cellular models of PTC, frozen human 
thyroid tumors expressed significantly more LGR5 by 
mRNA and protein analysis than adjacent benign frozen 
thyroid tissue samples (n = 4 normal tissue samples, 
n = 6 tumor samples) [Figure 1C]. Immunohistochemical 
staining of human PTC demonstrated variable expression 
of LGR5 and RSPO2 between patient samples, with some 
patients strongly expressing the protein and others completely 
devoid of expression [Supplementary Figures S1 and 2]. 
In several cases, there was striking intra-tumoral heteroge-
neity [Supplementary Figure S3].
LGR5 expression potentiates Wnt/β-catenin 
signaling in papillary thyroid cancer
RSPO-LGR5 signaling has been shown to potentiate 
Wnt/β-catenin signaling in other tissues, particularly in 
colorectal carcinoma (CRC). We effectively demonstrated 
that treatment of in vitro human PTC cell lines with RSPO 
ligand enhanced LGR5, B-catenin and Axin2 mRNA 
expression, whereas treatment of the cell lines with Wnt 
antagonist, niclosamide, effectively down-regulated Wnt 
target genes and LGR5 expression [Figures 2C]. Direct 
evidence for manipulation of human PTC cell lines in 
Wnt/β-catenin signaling was confirmed by TOP/FOP flash 
assay after treatment of these cell lines with niclosamide, 
and cell death was observed in a dose-dependent manner 
by both visual observation of floating cells and by 
viability count using Trypan Blue and a hemocytometer 
(observational data not shown) [Figure 2B]. Results were 
similar in all TPC-1, KTC-1 and Nthy-ori-3-1 in vitro 
models.
LGR5 is important in cellular migration and 
proliferation
Overexpression of LGR5 constructs in human cell 
lines had no effect on cellular phenotype or proliferation, 
likely due to overexpression at baseline. Conversely, 
silencing of LGR5 by shRNA showed impressive effects on 
reduced cellular migration by scratch assay, suggesting that 
it may be important in tumor migration and aggressiveness 
[Figures 3A–3C, Supplementary Figures S4 and S5]. 
CCK8 assay demonstrated no effects of shRNA on cellular 
proliferation in these cell lines [data not shown].
LGR5 overexpression in human PTC is 
associated with tumor aggressiveness and 
metastatic disease
In three separate PTC human cohorts treated at 
Duke from 2005–2013, we demonstrated that LGR5 
positivity was highly associated with markers of tumor 
aggressiveness. Our Discovery Cohort (n = 26 patients) 
demonstrated that LGR5 positivity was significantly 
associated with male gender (p = 0.009), vascular 
invasion (p = 0.015), and lymph node positivity (p < 
0.0001) [Table 1]. In LGR5-positive tumors associated 
with metastatic lymph nodes, tumor foci in lymph nodes 
were similarly LGR5 positive [Supplementary Figure S6]. 
In a small cohort of tumors that showed heterogeneous 
LGR5 expression (n = 6 tumors), corresponding lymph 
node metastases were all LGR5 positive, suggesting that 
the LGR5 population of tumoral cells were migratory to 
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loco regional sites. Because PTC is classically associated 
with lymph node metastasis in up to 60% of patients 
at presentation, we wished to ensure that we were 
evaluating patients who had a representative sample 
of nodes dissected at initial surgery. Therefore, in our 
Validation Cohort (n = 157 patients), we ensured that 
all patients underwent total thyroidectomy with at least 
5 lymph nodes sampled at surgery. In this population, 
we found significant association of LGR5 with markers 
of tumor aggressiveness, including primary tumor 
size (p = 0.010), lymph node metastases, and N stage 
(p < 0.0001), number of nodal metastases (< 0.0001), 
T Stage (p = 0.0104), vascular invasion (p < 0.0001), 
microscopic extra-thyroidal extension (p < 0.0001), 
capsular invasion (p = 0.0140), and macroscopic invasion 
(p = 0.007) [Table 2]. LGR5 positivity was associated 
with male gender, which is a known risk factor for more 
aggressive tumors. LGR5 also was associated with more 
aggressive histology, particularly the tall cell variant 
of PTC (p = 0.0008). Multifocality was associated with 
LGR5 negative dominant tumors. As a biomarker, LGR5 
positivity in the Validation Cohort predicted the presence 
of lymph node metastasis with a 95.5% sensitivity (95% 
CI 88.8%–98.7%) and 61% specificity (95% CI: 48.4%–
72.4%); it had a negative predictive value (NPV) of 91.3% 
(95% CI 79.2%–97.5%) for metastatic disease to lymph 
nodes. In the validation cohort, RSPO2 positivity strongly 
correlated with LGR5 tumor expression (p < 0.0001), 
with 80% of LGR5-positive tumors also staining positive 
for ligand RSPO2 [Supplementary Figure S2]. RSPO2-
positivity was strongly associated with nodal metastases 
(p = 0.029). Double-positive tumors (for LGR5 and 
RSPO2) were significantly associated with nodal 
metastases (p < 0.0001), number of lymph nodes positive 
(p = 0.0093), lymphovascular invasion (p = 0.0491), and 
extrathyroidal extension (p = 0.0355).
Figure 1: LGR5 and RSPO are induced in human thyroid cancer. Total RNA was isolated from Nthy-ori 3–1, a normal human 
thyroid cell line, and PTC cell lines TPC-1 and KTC-1. Expression of A. LGR5 and B. RSPO1–3 were quantified by qRT-PCR. Results 
are normalized to β-actin gene expression and expressed as mean fold-over Nthy-ori-3-1 for each gene (n = 3 independent isolations). 
C. LGR5 mRNA expression in normal frozen human tissue samples (n = 4 samples) and papillary thyroid cancer samples (n = 6 samples). 
D. Representative immunohistochemistry confirming elevated protein expression of both LGR5 and RSPO2 in patients with pathologically 
characterized PTC relative to normal thyroid tissue (magnification x20). Significance p < 0.05**.
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LGR5 is more highly expressed in PTC that 
harbors the BRAFV600E mutation
Because the BRAFV600E mutation is known to be 
associated with higher risk of recurrence, more aggressive 
histology, and increased risk for lymph node and distant 
metastases [32], we assessed whether there was association 
between LGR5 positivity and the BRAFV600E mutation. 
Using frozen human tissue samples, we measured LGR5 
mRNA expression in normal thyroid tissue and in PTC 
tissue with and without the BRAFV600E mutation 
(n = 4 patient samples/group). LGR5 mRNA expression 
was 3-fold higher in BRAFV600E mutation positive 
tumors than in tumors with wild type expression 
[Figure 4A]. In a separate cohort of 33 human patients with 
known BRAFV600E mutational status, LGR5 positivity 
was strongly associated with BRAFV600E mutational 
positivity by protein analysis (p = 0.005), strengthening 
the conclusion that LGR5 tumor positivity is associated 
with markers of tumor aggressiveness [Figure 4B]. In 
tumors that harbored the BRAFV600E mutation, 92% also 
were found to be LGR5 positive [Figure 4C].
DISCUSSION
Our data is the first to report that LGR5 and its 
ligand, RSPO2, are associated with tumor aggressiveness, 
lymph node metastases, and Wnt/β-catenin activation in 
human papillary thyroid cancer.
Both the TPC-1 and KTC-1 cell lines harbor 
mutations that up-regulate MAPK/ERK signaling cascades 
(RET/PTC1 and BRAFV600E, respectively). Previous 
Figure 2: TPC-1 cells demonstrate native Wnt/β-catenin signaling with pharmacologic manipulation. A. TPC-1 cells 
were treated either with increasing concentrations of recombinant RSPO1 for 24, 48 and 72 hours and LGR5 expression was examined 
by qRT-PCR. Results represent the mean of three independent experiments expressed as fold over vehicle (VEH) control for each time 
point. *P < 0.05; **P ≤ 0.01 B. TPC-1 cells were transfected with TOPFLASH or FOPFLASH as indicated and treated with either vehicle 
(DMSO), 0.5 uM, or 2.0 uM niclosamide for either 24 or 48 hours. Renilla luciferase plasmid was as normalization control and results are 
expressed as mean fold-change from baseline (vehicle; n = 2). C. TPC-1 cells were treated with compounds to either inhibit (niclosamide) 
or activate (RSPO) the Wnt pathway. TPC-1 cells were treated either with recombinant RSPO1 or niclosamide at the indicated doses for 48 
hours and mRNA expression levels for LGR5, Axin2 and β-catenin were quantified. Values were normalized to β-actin housekeeping gene 
expression and expressed as the fold over DMSO control (mean ± SEM; n = 3). Significance p < 0.05**.
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studies have suggested that up-regulation of MAPK/
ERK is associated with β-catenin stabilization and TCF-
mediated nuclear transcription. The exact mechanism for 
this synergistic process is yet unclear, but our data supports 
an existing body of literature suggesting that simultaneous 
up-regulation of MAPK/ERK and Wnt/β-catenin promotes 
tumor migration and metastases [33, 34].
Our findings also support a growing body of 
literature associating LGR5 with aggressiveness in 
other cancer subtypes including: colorectal, gastric, and 
cervical cancers, as well as malignant glioma [35–42]. In 
these tumors, LGR5 has been associated with increased 
cellular proliferation, resistance to chemotherapy, and 
compromised patient survival [38, 39]. Supporting 
evidence that LGR5 is an important marker of tumor 
aggressiveness has emerged particularly in the arena of 
colorectal cancer . Similar to our findings, evaluation 
of human colorectal tumors by IHC demonstrated that 
LGR5 over-expression was more frequently found 
in the metastatic lymph nodes and distant metastases 
when compared with primary colorectal cancer tissue. 
Additionally, cancer cells in the invasive front presented 
stronger LGR5 immunoreactivity than that at tumor center 
(P < 0.05) [39]. Three larger human studies (n = 366 
patients, n = 192 patients, n = 2139 patients) similarly 
found that LGR5 colorectal cancer tumor expression 
was significantly associated with higher American Joint 
Committee on Cancer (AJCC) staging, increased Ki67 
indices, advanced histological grade, increased depth of 
invasion, presence of nodal and distant metastases, and 
was independently associated with compromised overall 
patient survival [41, 42]. Taken together, these findings 
suggest that LGR5 may be both a prognostic marker and a 
potential target for patients with aggressive and metastatic 
tumors.
PTC is associated with low overall mortality 
but high increased morbidity and risk for loco regional 
recurrence [43]. Therefore, although patients are usually 
not at high risk for death, they are subject to repeat 
ultrasound surveillance, serologic and radiographic testing, 
Figure 3: shRNA-mediated decrease in LGR5 expression results in inhibition of cell migration. TPC-1 clonal cells 
harboring stable expression for either non-targeting (Ctrl) shRNA A. or targeting human LGR5 shRNA B. were subjected to a wound 
healing assay for 24 and 48 h. Representative images are shown. Leading edges of repairing cell monolayers are indicated by red bars. 
Briefly, cells were grown to 80% confluence at which time cells were removed with a P200 tip. Images were then acquired at 0 h, 24 h, 
and 48 h and analyzed by Olympus software to measure ability of the cells to repair the wound. C. Cellular migration was quantified and 
represented graphically with results expressed as mean ± SEM of three independent measurements. Significance p < 0.05*.
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and accumulating health care costs as part of lifelong 
monitoring for demonstration of persistent or recurrent 
disease. An overwhelming majority of recurrences are 
found in loco regional lymph nodes, potentially prompting 
higher-risk remedial surgery, increased iodine-131 (I-131) 
cumulative doses, and as a result increased risk of patient 
Table 1: The Discovery Cohort (n = 26 patients)
Discovery Cohort 
Characteristics
LGR5 – (n = 10 patients) LGR5 + (n = 16 patients) p value
Male Sex 12.5% 66.67% 0.009
Age (years) 47.6 49.0 0.794
Tumor Size (mean size +/– 
std dev)
2.67 cm (+/–2.1 cm) 2.08 cm (+/–1.08 cm) 0.860
PTC Variant
Classical = 6 (60%)
Follicular Variant = 3 (30%)
Classical + Follicular Variant = 1 (10%)
Classical = 9 (56.25%)
Follicular Variant = 3 (18.75%)
Classical + Follicular Variant = 4 
(25%)
0.567
Lymph Node Positivity 0% 81.3% <0.0001
Multifocality 20% 50% 0.126
Encapsulated 0% 21.43% 0.118
Vascular Invasion 0% 33.33% 0.015
Extrathyroidal Extension 0% 13.33% 0.142
Positive Margins 10% 25% 0.345
Patient and tumor characteristics are reported along with LGR5 tumor status by immunohistochemistry. Significance is 
highlighted in red and is p < 0.05**
Table 2: The Validation Cohort (n = 157 patients)
Validation Cohort 
Characteristics
LGR5 – (n = 48 patients) LGR5 + (n = 109 patients) p value
Male Sex 19.6% 26.1% <0.0001**
Age (years) 44.5 (+/–14.1) 44.0 (+/–16.6) 0.851
Tumor Size (cm) (mean size 
+/– std dev)
1.6 (+/–1.3) 2.3 (+/–1.6cm) 0.010*
PTC Variant
Classical= 30.8%
Follicular Variant = 69.2%
Tall cell variant = 0%
Classical = 68.6%
Follicular Variant = 25.7%
Tall cell variant = 8.6%
0.0008**
Lymph Node Positivity 8.3% 75.2% <0.0001**
Lymph Node Number 0.7 +/–2.6 6.2 +/–8/1 <0.0001**







Vascular Invasion 8.7% 33.6% <0.0001**
Extrathyroidal Extension 2.2% 26.4% <0.0001**
Capsular Invasion 10.9% 14.5% 0.0140*
Macroscopic Invasion 0% 2.8% 0.007**
Patient and tumor characteristics are reported along with LGR5 tumor status by immunohistochemistry. Significance is 
highlighted in red and is p < 0.05**
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morbidity. On average, 7% of all PTC patients have 
persistent PTC in the first year following treatment, and 
another 2% of patients recur over 8–10 years of follow-up; 
nevertheless, many patients undergo a lifetime of extensive 
surveillance testing. Risk for recurrence is strongly 
associated with tumor risk stratification largely based on 
tumor histology, with only 2.5% of low-risk patients but 
up to 70% of high-risk patients found to have persistent 
disease within the first postoperative year [42]. Because 
current treatment methods cannot predict risk stratification 
pre-operatively (prior to tissue analysis), extent of initial 
surgery is currently left to physician discretion (based on 
surgeon preference, tumor size, patient age, and highly 
variable operator-dependent preoperative ultrasonography) 
[39]. Pre-operative dilemmas of not knowing the exact 
tumor size prior to surgical resection, inability to assess 
for markers of tumor aggressiveness, and compromised 
ultrasonographic assessment of lymph node status in the 
central neck compartment prior to thyroidectomy (because 
of the overlying thyroid gland) can severely restrict the 
ability to make an informed decision on the appropriate 
extent of surgery [44, 45]. These challenges are reflected 
in discordance among surgical guidelines internationally; 
the American Thyroid Association, for example, endorses 
total or hemi thyroidectomy without prophylactic node 
dissection [44], while the Japanese guidelines suggest 
prophylactic central neck lymph node dissection +/− 
lateral neck lymph node dissection at the time of primary 
surgery due to the high incidence of microscopic lymph 
node metastases with PTC (upwards of 60–70% at 
diagnosis) [45]. Therefore, it would be beneficial to 
be able to accurately predict preoperatively tumoral 
behavior and risk for metastatic disease in order to: (1) 
reduce postoperative long-term surveillance in low risk 
patients and (2) perform the best initial surgery, thereby 
minimizing persistence/recurrence and repeat medical and 
surgical intervention in intermediate and high risk patients.
We demonstrated in two separate cohorts of PTC 
patients that LGR5 positivity is associated with aggressive 
histological characteristics such as lymphovascular 
invasion, increased tumor size, microscopic extra 
thyroidal extension, capsular invasion, macroscopic 
Figure 4: LGR5 tumoral positivity is associated with the BRAFV600E mutation. A. Expression of LGR5 in frozen 
normal human thyroid tissue (n = 4 normal samples) and in BRAFV600E tumor negative and positive samples (n = 3 samples/group). 
B. Representative IHC tumor samples for LGR5 (brown DAB staining) in BRAFV600E negative patients (1–3) and BRAFV600E positive 
patients (4–6). C. In a cohort of 33 human patients with known BRAFV600E mutational status, LGR5 positivity was strongly associated 
with the BRAFV600E mutation (p = 0.005**). In those who were BRAFV600E positive, 92% were also LGR5 positive (black) while 8% 
were LGR5 negative (grey). Significance p < 0.05**.
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invasion, and more aggressive tumor type. It is associated 
with increased TNM stage, increased number of 
metastatic lymph nodes, and BRAFV600E positivity. 
LGR5 positivity is also associated with male gender, 
which is a demographic characteristic associated with, on 
average, more aggressive tumor behavior. Interestingly, 
established markers of PTC recurrence including ETE 
and more than 5 metastatic lymph are also associated 
with LGR5 and RSPO2 positivity. Further research is 
needed to determine whether LGR5 overexpression may 
be beneficial as a preoperative biomarker and tool for risk 
stratification. Tumor positivity may help direct surgical 
approach and postoperative surveillance. Additionally, 
LGR5 may serve as a novel target for the management 
of aggressive PTC. Accordingly, there is a need to better 
understand the role that LGR proteins and RSPO proteins 
play in carcinogenesis and metastasis. Future studies will 
focus on delineating the mechanism for enhanced LGR5-
induced tumoral migration and development of LGR5 as 
a pre-operative biomarker and as a prognostic marker of 
disease-specific morbidity/recurrence in human PTC.
MATERIALS AND METHODS
Human cell lines and cell culture
Human papillary thyroid cancer cell lines (TPC-1 
and KTC-1) were grown in RPMI1640 media (Sigma-
Aldrich). The immortalized normal human thyroid cell 
line (Nthy-ori-3-1, ATCC) was cultured in RPMI 1640 
supplemented with 2 mM glutamine and 10% fetal 
bovine serum (FBS) (Sigma-Aldrich). All media were 
supplemented with 10% heat-inactivated FBS (Invitrogen, 
Carlsbad, CA, USA) and 1% penicillin-streptomycin 
(10,000 units penicillin and 10 mg streptomycin per mL 
in 0.9% NaCl, Sigma-Aldrich). Culturing was carried out 
at 37°C with 5% carbon dioxide.
Drug manipulations
Wnt signaling was assessed at baseline in Nthy-
ori-3-1, TPC-1 and KTC-1 cell lines. Human cell lines 
were treated with recombinant human R-Spondin1 
(RSPO1, R&D Systems, 4645-RS-025) at varying 
concentrations in a dose-dependent manner (0 ng/ml, 50 
ng/ml, and 150 ng/ml) and harvested after 48 hours for 
mRNA and protein. Additionally, cell lines were treated 
with increasing doses of niclosamide (0 μM, 0.3 μM, 
and 1 μM), a Wnt/β-catenin antagonist, and harvested at 
48 hours. All drug doses were consistent with published 
literature utilizing oncogenic cell lines [30].
Quantitative real-time PCR (qRT-PCR)
RNA was isolated from individual cell lines and 
frozen human thyroid tissue using Direct-zol RNA 
Miniprep kit (ZYMO, R2052) and quantified by Nanodrop 
2000 (Thermo Scientific). RNA was reverse transcribed 
to cDNA using random primer and Superscript RNase 
Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) and 
amplified using the StepOne Plus real-time PCR platform 
(ABI/Life Technologies). qRT-PCR was performed with 
denaturation at 95°C for 3 minutes, followed by 40 cycles of 
denaturing at 95°C for 10 seconds and annealing-extension 
at the optimal primer temperatures for 60 seconds. Target 
gene threshold cycles (Ct) were analyzed according to the 
2-ΔΔCt method relative to human beta actin housekeeping 
gene. All analyses were performed in triplicate. Primer 
sequences can be found in Supplementary Material.
TOP/FOP-flash assay
We used a TOP/FOP-Flash reporter assay reflecting 
beta-catenin activation of TCF-LEF mediated transcription 
and Wnt pathway activity, as described [31]. Briefly, TOP-
Flash and FOP-Flash plasmids (2 μg) were transfected 
into tumor cells with JetPrime (Polyplus Transfection) in 
24-well plates and treated with either vehicle (DMSO) or 
niclosamide (1 μM, Sigma). pTK-RL plasmid encoding 
Renilla luciferase (0.1 μg, Promega) was used as reference 
plasmid. The activity of both luciferase reporters was 
determined at 48 hours after transfection using the Dual 
Luciferase Assay kit (Promega, Madison, WI, USA), 
according to the manufacturer’s instructions. The TOP-
Flash reporter activity is presented as the relative ratio of 
firefly luciferase activity to Renilla luciferase activity. All 
experiments were performed in triplicate.
Overexpression and knockdown of LGR5
TPC-1 cells stably overexpressing either non-targeting 
(Control, Ctrl) or three distinct LGR5 targeting shRNAs 
(Origene) were isolated. One day prior to transfection 
of plasmids harboring unique LGR5 shRNA silencing 
sequences, TPC-1 cells were seeded at 50% confluency on 
6-well tissue culture plate. 5 ng/ul of three distinct plasmids 
harboring LGR5 shRNAs (Origene; TF311747) were added 
with JetPrime transfection reagent to each well according 
to the manufacturer’s protocol. Transfection efficiency 
was monitored by fluorescent microscopy to visualize red 
fluorescent protein expression of an integrated turboRFP 
element in the plasmid. Cells stably overexpressing LGR5-
targeting shRNA were selected using puromycin antibiotic 
(Sigma) at a previously optimized concentration of 5 μg/ml. 
Clonal populations were isolated, expanded and maintained 
under puromycin selection.
Cellular viability assays
Cell viability was measured using the Cell 
Counting Kit-8 (CCK8; Dojindo Molecular Technologies, 
Gaithersburg, Maryland, USA). Briefly, wild-type TPC-1 
cells, and TPC cells stably expressing either non-targeting 
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shRNA or LGR5 shRNA were plated and cell growth 
measured over 48 hours. Absorbance measurements 
were made by the FluoroStar Optima plate reader (BMG 
Labtech) at excitation filter 465 nm. Measurements were 
performed in triplicate.
Wound-healing assay
A wound-healing assay was performed by scraping 
cell monolayers. Cells were plated at 80% confluency, and 
a wound was made using a P200 tip. A reference mark 
was created on the dish, and a time 0 image was acquired. 
Subsequent images were taken in the matched region at 
the indicated times, and the distance of the wound-healing 




Using the IRB-approved Duke Clinical and 
Pathologic Database conducted according to the principles 
expressed in the Declaration of Helsinki, we identified a 
discovery cohort of patients with PTC (n = 26 patients) 
and associated clinical-histologic characteristics. To 
confirm preliminary findings, we identified a validation 
cohort of patients (n = 157 patients) treated at Duke 
from 2005–2013 who had undergone total thyroidectomy 
with at least 5 lymph nodes sampled at surgery (n = 71 
patients with N0 disease and 86 patients with N1 disease). 
Surgeries were performed by a variety of surgeons 
(n = 7) at our institution. A separate cohort of patients 
(n = 33 patients) with known BRAFV600E tumor 
mutational status was evaluated for association of this 
mutation with LGR5 positivity Figure 4.
Immunohistochemistry
The immunohistochemical staining procedure was 
performed on unstained paraffin-embedded slides. Briefly, 
formalin-fixed and paraffin-embedded tissue sections 
(5 μm thick) were deparaffinized in xylene and rehydrated 
through descending concentrations of ethanol. Endogenous 





) for 14 minutes on all tissue specimens. In each 
case, a control slide was incubated with DAB substrate 
solution after rehydration to water to confirm quenching 





. After antigen retrieval was performed by heating 
in 10 mM citrate buffer (pH 6.0) + 0.05% TWEEN20 
for 20 min, the sections were treated with protein block 
(DAKO Envision, Carpinteri, CA). Primary antibodies 
for LGR5 (Origene, TA301323, 1:500 dilution) and 
RSPO2 (Origene, NBP1–81093 1:500 dilution) were 
added to tissue sections and incubated overnight at 4°C. 
A secondary control was used for each run with omission 
of the primary. A horseradish peroxidase- conjugated 
rabbit or mouse secondary antibody was added for 60 min 
at room temperature, followed by 3,3′-diaminobenzidine 
(DAB) development (DAB Substrate Chromogen System, 
Dako) and hematoxylin and eosin (H&E) as per standard 
staining protocol. Slides were fixed and images obtained 
with the Olympus IX71 inverted microscope using the 
DP2-BSW Olympus image acquisition software system. 
LGR5 and RSPO2 tumor staining was classified into two 
categories: negative or positive expression. All slides 
were reviewed in triplicate in a blinded manner. Staining 
was performed on primary tumor samples (n = 208 total 
patients) and in a representative cohort of corresponding 
lymph node metastatic samples (n = 12 patients).
Statistical analysis
A statistical analysis was performed using JMP 
software, version 10 (Cary, NC). For comparison among 
the groups, a Student’s t test, Chi-Square test or a Fisher’s 
Exact test followed by a post hoc Tukey test was performed, 
and p < 0.05 was defined as statistically significant. The 
data and error bars report the means ± SEM.
Study approval
The Duke Institutional Animal Care and Use 
Committee and the Institutional Review Board 
approved all animal and human studies in compliance 
with Duke University Ethical and Research standards. 
Duke University conducts all research according to the 
Declaration of Helsinki principles.
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